At 7.7% CAGR, Asia Pacific Hyperpigmentation Disorder Treatment Market is Projected to be Worth US$ 4,468.99 Million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific hyperpigmentation disorder treatment market was valued at US$ 2,462.36 million in 2022 and is expected to reach US$ 4,468.99 million by 2030, registering a CAGR of 7.7% from 2022 to 2030. Increasing number of hyperpigmentation disorder awareness programs and rise in prevalence of melasma are among the critical factors attributed to drive the Asia Pacific hyperpigmentation disorder treatment market growth.

Campaigns to raise awareness about UV-induced skin hyperpigmentation are essential to educate the general populace on the prevention, screening, diagnosis, and treatment of these conditions; they also discuss the importance of using good-quality sunscreen products to manage these disorders. In June 2021, Dermalogica Clear launched a campaign to encourage skin acceptance and educate audiences on post-inflammatory hyperpigmentation, acne, breakouts, and more. Zydus Healthcare, India, executed the nationwide Melasma Awareness Movement, also known as the “Face the World” campaign, from April 1 to May 31, 2023, to enhance awareness about melasma. In August 2023, Zydus Healthcare set a record for maximum health care professionals (HCPs) joining this campaign with the participation of 18,737 HCPs in the campaign, who contributed to making a vast number of patients aware of melasma. The increased awareness of melasma and other hyperpigmentation disorders has led to a surge in demand for innovative and efficacious treatment products and procedures. Moreover, it has brought about a significant and positive change in how society understands and manages hyperpigmentation. Thus, the increasing number of awareness programs bolsters the growth of the hyperpigmentation disorder treatment market.

On the contrary, high cost of treatments hampers the growth of Asia Pacific hyperpigmentation disorder treatment market.

By treatment type, the Asia Pacific hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held 42.1% share of Asia Pacific hyperpigmentation disorder treatment market share in 2022, amassing US$ 1,035.60 million. It is projected to garner US$ 1,947.84 million by 2030 to register 8.2% CAGR during 2022–2030.

In terms of condition, the Asia Pacific hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held 47.1% share of Asia Pacific hyperpigmentation disorder treatment market share in 2022, amassing US$ 1,159.50 million. It is projected to garner US$ 2,160.36 million by 2030 to register 8.1% CAGR during 2022–2030.

Based on end user, the Asia Pacific hyperpigmentation disorder treatment market is hospitals, dermatology centers, and others. The hospital segment held 47.7% share of Asia Pacific hyperpigmentation disorder treatment market share in 2022, amassing US$ 1,175.26 million. It is projected to garner US$ 2,118.48 million by 2030 to register 7.6% CAGR during 2022–2030.

Based on country, the Asia Pacific hyperpigmentation disorder treatment market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that India captured 31.2% share of Asia Pacific hyperpigmentation disorder treatment market in 2022. It was assessed at US$ 768.60 million in 2022 and is likely to hit US$ 1,411.89 million by 2030, registering a CAGR of 7.9% during 2022–2030.

Key players operating in the Asia Pacific hyperpigmentation disorder treatment market are AbbVie Inc, Bayer AG, Galderma SA, L’OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Pierre Fabre SA, among others.

• In February 2024: L'Oréal Paris launched the Glycolic Bright Dark Circle Eye Serum, a groundbreaking solution for under-eye hyperpigmentation and puffiness. The serum, formulated with a blend of 3 percent Glycolic Acid, Vitamin CG, and Niacinamide, promises to diminish dark circles by -49% in just two weeks. The serum is priced at Rs 699 and is ophthalmologically tested, suitable for all skin types, and clinically proven to treat visible dark circles.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com